JP2012501165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012501165A5 JP2012501165A5 JP2011509333A JP2011509333A JP2012501165A5 JP 2012501165 A5 JP2012501165 A5 JP 2012501165A5 JP 2011509333 A JP2011509333 A JP 2011509333A JP 2011509333 A JP2011509333 A JP 2011509333A JP 2012501165 A5 JP2012501165 A5 JP 2012501165A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- depdc1
- polypeptide
- znf224
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
- 229920001184 polypeptide Polymers 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 101000950642 Homo sapiens DEP domain-containing protein 1A Proteins 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 20
- 102100037753 DEP domain-containing protein 1A Human genes 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 101000782150 Homo sapiens Zinc finger protein 224 Proteins 0.000 claims description 14
- 102100036562 Zinc finger protein 224 Human genes 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 206010005003 Bladder cancer Diseases 0.000 claims description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 230000002103 transcriptional effect Effects 0.000 claims description 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 8
- 102100024099 Disks large homolog 1 Human genes 0.000 claims description 6
- 101001053984 Homo sapiens Disks large homolog 1 Proteins 0.000 claims description 6
- 101000951365 Homo sapiens Disks large-associated protein 5 Proteins 0.000 claims description 6
- 108700008625 Reporter Genes Proteins 0.000 claims description 6
- 108010047933 Tumor Necrosis Factor alpha-Induced Protein 3 Proteins 0.000 claims description 6
- 102000007150 Tumor Necrosis Factor alpha-Induced Protein 3 Human genes 0.000 claims description 6
- 210000000170 cell membrane Anatomy 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 claims description 4
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 claims description 4
- 230000008827 biological function Effects 0.000 claims description 4
- 230000005907 cancer growth Effects 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 108010062307 AAVALLPAVLLALLAP Proteins 0.000 claims description 2
- 101800002011 Amphipathic peptide Proteins 0.000 claims description 2
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 2
- 108010061875 HN-1 peptide Proteins 0.000 claims description 2
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims description 2
- 108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 claims description 2
- 108010088535 Pep-1 peptide Proteins 0.000 claims description 2
- 102000029797 Prion Human genes 0.000 claims description 2
- 108091000054 Prion Proteins 0.000 claims description 2
- 101710149951 Protein Tat Proteins 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 108010025307 buforin II Proteins 0.000 claims description 2
- UKVZSPHYQJNTOU-IVBHRGSNSA-N chembl1240717 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-IVBHRGSNSA-N 0.000 claims description 2
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 claims description 2
- 108010043655 penetratin Proteins 0.000 claims description 2
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims description 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 2
- 108010011110 polyarginine Proteins 0.000 claims description 2
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 claims description 2
- 108010062760 transportan Proteins 0.000 claims description 2
- UKVZSPHYQJNTOU-GQJPYGCMSA-N (2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoic acid Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-GQJPYGCMSA-N 0.000 claims 1
- 108091081021 Sense strand Proteins 0.000 description 5
- 101150068708 ZNF224 gene Proteins 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19053108P | 2008-08-28 | 2008-08-28 | |
| US61/190,531 | 2008-08-28 | ||
| PCT/JP2009/004006 WO2010023850A1 (en) | 2008-08-28 | 2009-08-21 | Method for treating or preventing bladder cancer using the depdc1 polypeptide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012501165A JP2012501165A (ja) | 2012-01-19 |
| JP2012501165A5 true JP2012501165A5 (enExample) | 2012-10-04 |
| JP5640263B2 JP5640263B2 (ja) | 2014-12-17 |
Family
ID=41721034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509333A Expired - Fee Related JP5640263B2 (ja) | 2008-08-28 | 2009-08-21 | Ｄｅｐｄｃ１ポリペプチドを使用した膀胱癌の治療または予防のための方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8975086B2 (enExample) |
| EP (1) | EP2362904B1 (enExample) |
| JP (1) | JP5640263B2 (enExample) |
| WO (1) | WO2010023850A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2476699B1 (en) | 2006-10-17 | 2015-06-17 | Oncotherapy Science, Inc. | Peptide vaccines for cancers expressing DEPDC1 polypeptides |
| KR101886452B1 (ko) | 2010-07-14 | 2018-09-07 | 큐알엔에이, 인크. | 디스크 라지 호모로그(dlg)에 대한 천연 안티센스 전사체의 저해에 의한 dlg 관련된 질환의 치료 |
| JP6009154B2 (ja) * | 2011-10-19 | 2016-10-19 | 国立大学法人 岡山大学 | 細胞膜透過型ホウ素ペプチド |
| WO2015083685A1 (ja) * | 2013-12-04 | 2015-06-11 | 国立大学法人東京医科歯科大学 | Ｄｌｇ１／ＳＡＰ９７遺伝子のスプライシングバリアント、及びスプライシングバリアントを利用した統合失調症の検出 |
| SG10201913592QA (en) * | 2015-08-12 | 2020-02-27 | Oncotherapy Science Inc | Depdc1-derived peptide and vaccine containing same |
| JP6320469B2 (ja) * | 2016-07-15 | 2018-05-09 | 国立大学法人 岡山大学 | 細胞膜透過型ホウ素ペプチド |
| US10511690B1 (en) | 2018-02-20 | 2019-12-17 | Intuit, Inc. | Method and apparatus for predicting experience degradation events in microservice-based applications |
| JP7422498B2 (ja) * | 2019-07-25 | 2024-01-26 | 芳武 村山 | ペプチド、細胞遊走抑制剤、細胞浸潤抑制剤、がん細胞転移抑制剤、及び医薬 |
| KR102775653B1 (ko) * | 2021-09-15 | 2025-03-05 | 한국기초과학지원연구원 | 아르기닌 리치 펩타이드를 포함하는 단백질 분해제 및 이를 이용한 단백질 이상질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7001999B1 (en) * | 1998-04-15 | 2006-02-21 | Ludwig Institute For Cancer Research | Tumor associated nucleic acids and uses therefor |
| US20040241726A1 (en) * | 1999-01-06 | 2004-12-02 | Chondrogene Limited | Method for the detection of allergies related gene transcripts in blood |
| US20050123938A1 (en) | 1999-01-06 | 2005-06-09 | Chondrogene Limited | Method for the detection of osteoarthritis related gene transcripts in blood |
| US7030215B2 (en) * | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| WO2002031111A2 (en) | 2000-10-12 | 2002-04-18 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| ATE536187T1 (de) | 2000-10-19 | 2011-12-15 | Epimmune Inc | Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen |
| WO2003083074A2 (en) | 2002-03-28 | 2003-10-09 | Idec Pharmaceuticals Corporation | Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas |
| EP2011885B1 (en) * | 2005-02-10 | 2015-04-22 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| EP2336316A1 (en) | 2005-07-27 | 2011-06-22 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
| EP2476699B1 (en) * | 2006-10-17 | 2015-06-17 | Oncotherapy Science, Inc. | Peptide vaccines for cancers expressing DEPDC1 polypeptides |
-
2009
- 2009-08-21 US US13/061,064 patent/US8975086B2/en not_active Expired - Fee Related
- 2009-08-21 WO PCT/JP2009/004006 patent/WO2010023850A1/en not_active Ceased
- 2009-08-21 EP EP09809506.0A patent/EP2362904B1/en not_active Not-in-force
- 2009-08-21 JP JP2011509333A patent/JP5640263B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012501165A5 (enExample) | ||
| JP2010500003A5 (enExample) | ||
| US12037579B2 (en) | Synthetic RNA binding polypeptides | |
| Wang et al. | Development of peptidomimetic inhibitors of the ERG gene fusion product in prostate cancer | |
| RU2010111120A (ru) | Eb13, dlx5, nptx1 и cdkn3 в качестве генов-мишеней для терапии и диагностики рака легкого | |
| RU2009109692A (ru) | Лечение или предотвращение развития злокачественных опухолей, сверхэкспрессирующих reg4 или kiaa0101 | |
| JP6014904B2 (ja) | Ｅｒａｐ１由来ペプチド及びその使用 | |
| JP2010512730A5 (enExample) | ||
| JP2002522009A5 (enExample) | ||
| JP2012501164A5 (enExample) | ||
| NO317934B1 (no) | Fremgangsmate for beskyttelse og pavisning av en nukleinsyresekvens ved a anvende en nukleinsyreanalog, fremgangsmate for utforelse av en nukleinsyreamplifikasjon og fremgangsmate for opparbeidelse av reaksjonsprodukt derav. | |
| TW200831673A (en) | TTK as tumor marker and therapeutic target for lung cancer | |
| JP2022031646A (ja) | Ａｔｆ５ペプチド多様体及びそれらの使用 | |
| JP5640263B2 (ja) | Ｄｅｐｄｃ１ポリペプチドを使用した膀胱癌の治療または予防のための方法 | |
| JP2010523081A5 (enExample) | ||
| JP2010131022A5 (enExample) | ||
| US10865229B2 (en) | Synthetic MBNL proteins for treatment of repeat expansion disease | |
| RU2011111532A (ru) | Твс1d7 в качестве опухолевого маркера и терапевтической мишени в случае злокачественной опухоли | |
| Vezenkov et al. | Structure–Activity Relationships of JMV4463, a Vectorized Cathepsin D Inhibitor with Antiproliferative Properties: The Unique Role of the AMPA‐Based Vector | |
| CA2783669A1 (en) | Compositions comprising zinc finger domains and uses therefor | |
| JP2016520570A (ja) | Ａ型インフルエンザウイルス感染の治療又は予防に使用するためのｐａｒ−４アンタゴニスト | |
| WO2018175273A1 (en) | Erg targeted therapy | |
| JP2008545394A5 (enExample) | ||
| JP6619211B2 (ja) | 細胞核輸送受容体ｋｐｎａ２タンパク質に結合するアプタマー、及びそれを用いたｋｐｎａ２タンパク質の機能阻害 | |
| JP7726464B2 (ja) | Ｂｉｇ３－ｐｈｂ２相互作用阻害ｐｈｂ２由来ペプチドを含む乳がん治療薬 |